We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
-3.17%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
-$21.4M
Cap. Flow
-$116M
Cap. Flow %
-111.68%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$9.26M

Top Sells

Rank Stock Value
1
APEN
Apollo Endosurgery, Inc.
APEN
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 6.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
1
KALA BIO
KALA
$12.5M
$6.52M 6.28%
+534
New +$9.26M
APEN
2
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-252,079
Closed -$1.81M

Similar funds

BGC
Birch Grove Capital New York $9.51M AUM 0.22% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
JDR
Jay D. Rosenbaum $6.69M AUM 4.68% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
KIM
Kaizen Investment Management Singapore $6.23M AUM
RJTCONH
Raymond James Trust Company of New Hampshire Portsmouth, New Hampshire $12.1M AUM 28.84% 1-Year Est. Return
HSC
Harbor Spring Capital New York $12.3M AUM
HVM
Harvest Volatility Management Norwalk, Connecticut $4.39M AUM 13.08% 1-Year Est. Return

Athyrium Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Athyrium Capital Management held 4 positions worth $104M, down 17% from $125M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Athyrium Capital Management withdrew a net $116M in Q4 2018, closing 1 position. Its most notable exit was Apollo Endosurgery, Inc., an estimated $1.81M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, up from 1.4% a quarter earlier.

Against the trend, Athyrium Capital Management opened a new position in KALA BIO worth $6.52M.

  • Athyrium Capital Management's largest Q4 2018 buy was KALA BIO: 534 shares worth $6.52M.
  • Athyrium Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2018, selling an estimated $1.81M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $104M portfolio in Q4 2018.
  • Athyrium Capital Management opened 1 new position and closed 1 in Q4 2018.
  • Athyrium Capital Management's portfolio value fell 17% quarter-over-quarter to $104M.

Based on Athyrium Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.